Taro Pharmaceutical Industries Ltd.

Good morning, ladies and gentlemen, and welcome to the Tarot Pharmaceuticals Second Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. If anyone should require assistance during the conference, please press star, then zero, on your touch-tone telephone. As a reminder, this conference call is being recorded. I would now like to turn the call over to your host today, Mr. William Coote, Assistant Vice President and Treasurer. Please go ahead, sir.

William Coote Thank you. Good morning, everyone, and welcome to our second quarter 2020-21 earnings conference call. We hope everyone is healthy and safe during these trying times, and since safety is our top priority, we are conducting a virtual call. Joining me today are Mr. Dilashanti, Chairman of the Board of Directors. Mr. Uday Valdota, Taro's CEO, and Ms. Daphne Wang, Taro's CFO. We hope you have received a copy of the earnings press release, which can be found on our website at taro.com. We anticipate that many of you may have questions concerning not only this quarter's and year-to-date financial performance, but also our markets, operations, strategies, and other matters. While we will try to respond to most of your queries, we will not be able to share product-specific and commercially sensitive information, including pipeline details. As a reminder, this call is being recorded and a replay and call transcript will be made available on our website. Before we proceed, I must remind you that today's discussion may include certain forward-looking statements and in the meeting of the Private Securities Litigation Reform Act of 1995. Although the company believes the expectations reflected in such forward-looking statements to be based on reasonable assumptions, it can give no assurances that its expectations will be attained and should be viewed in conjunction with the risks that our business faces as detailed from time to time in the company's SEC reports. I would now turn the call over to Mr. Dilshandi. Thank you, Bill.

Welcome to all of you and thank you for joining us today for Taro's earning call after the announcement of second quarter and six month 2020-21 financial results. I hope that all of you remain safe and healthy. Taro's results are a reflection of these challenging times we are facing. However, as the COVID pandemic continues to impact the globe, Taro remains focused on delivering quality products to patients and communities that depend on them, while continuing to take the necessary precautions to safeguard the health and well-being of our employees. How the pandemic will evolve and what the long-term impact from COVID-19 will be, not only for Taro's business, but more importantly, on people's health around the world, is difficult to measure and anticipate. And as we have said for some time, we believe that the US generic market will continue to be competitive for the foreseeable future. On the positive side, September marks the 10th anniversary of Sun's majority ownership of Taro. During this time, the company has grown significantly and enjoyed many successes, including more than 75 links with the FDA and over 65 approvals. In addition, we have returned additional shareholder values in excess of $1.2 billion through a combination of shared repurchases, tender offers, and a special dividend. On behalf of the entire board of directors, I want to thank all the Taro employees for their continuing dedication and commitment to serving our customers and patients during this unprecedented time. I will now hand over the call to Uday.